ALS biomarker study completed: could immune signals unlock disease clues?
NCT ID NCT07260981
First seen Jan 02, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study looked at 60 people — half with ALS and half healthy — to measure specific immune and nerve damage markers in their blood and spinal fluid. The goal was to better understand how the immune system's interferon-alpha pathway relates to ALS. No treatment was given; the study aimed to find patterns that could help diagnose or track the disease in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pioneer Life Sciences Cherrywood
Dublin, Ireland
Conditions
Explore the condition pages connected to this study.